Apogem Capital’s ADMA Biologics ADMA Stock Holding History

Apogem Capital’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-38,346	Closed	-$67K	–	189
2021 Q1	$67K	Sell	38,346 -15,894	-29%	-$36.4K	0.05%	176
2020 Q4	$106K	Buy	+54,240	New	+$114K	0.07%	156

Other funds holding ADMA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Apogem Capital's ADMA Position: Q2 2021 in Review

Apogem Capital sold out of ADMA Biologics (ADMA) in Q2 2021, closing a stake of 38,346 shares — an estimated $67K sold.

Apogem Capital first reported a position in ADMA in Q4 2020 and held it in 2 quarters. The position peaked at $106K in Q4 2020. 90 funds tracked by Wall St. Rank hold ADMA as of Q2 2021.

Apogem Capital reported no remaining ADMA Biologics position as of Q2 2021 after selling out during the quarter.
Apogem Capital sold 38,346 ADMA Biologics shares in Q2 2021, an estimated $67K.
Apogem Capital first reported a position in ADMA Biologics in Q4 2020 and held it in 2 quarters.
Apogem Capital's ADMA Biologics position peaked at $106K in Q4 2020.
90 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2021.

Based on Apogem Capital's 13F filing for Q2 2021, filed 16 Aug 2021.